Zhenwei Peng, Wenzhe Fan, Zelong Liu, Han Xiao, Jian Wu, Rong Tang, Jianfei Tu, Liangliang Qiao, Fuxi Huang, Wenxuan Xie, Wenquan Zhuang, Wenbo Guo, Shaoqiang Li, Yunpeng Hua, Shunli Shen, Qiang He, Dongming Li, Jiaping Li, Ming Kuang
IMPORTANCE: Certain patients with hepatocellular carcinoma with portal vein tumor thrombus could benefit from surgical resection, and postoperative adjuvant therapy may lower the incidence of tumor recurrence. OBJECTIVE: To compare the efficacy and safety of sorafenib plus transarterial chemoembolization vs sorafenib alone as postoperative adjuvant therapy for patients with hepatocellular carcinoma with portal vein tumor thrombus. DESIGN, SETTING, AND PARTICIPANTS: This was a phase 3, multicenter, randomized clinical trial conducted in 5 hospitals in China...
April 3, 2024: JAMA Surgery